Related Experiment Video
Updated: Jul 17, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Cryoglobulinemia.
Alessandra Tedeschi1, Claudia Baratè, Ernesto Minola
1Department Oncology/Haematology, Division of Haematology, Nigurda Ca' Granda Hospital Milano, Italy. alessandra.tedeschi@ospedaleniguarda.it
Mixed cryoglobulinemia (MC) is linked to Hepatitis C Virus (HCV) infection, causing immune-complex vasculitis. Treating HCV and using rituximab can manage MC and associated B-cell disorders.
Area of Science:
- Immunology
- Virology
- Rheumatology
Background:
- Cryoglobulinemia involves cold-precipitating immunoglobulins in serum.
- Type I is monoclonal; Types II and III are mixed, often with rheumatoid factor activity.
- Mixed cryoglobulinemia (MC) syndrome is immune-complex vasculitis with purpura, weakness, and arthralgias.
Purpose of the Study:
- To explore the link between Hepatitis C Virus (HCV) infection and MC.
- To understand the role of viral infection in autoimmune phenomena and lymphoproliferative disorders.
- To evaluate therapeutic strategies for HCV-related MC.
Main Methods:
- Review of studies demonstrating HCV as a trigger for MC.
- Analysis of the B-cell stimulation pathway in HCV infection leading to monoclonal proliferation.
- Assessment of antiviral therapy and rituximab in MC management.
Main Results:
- HCV is a principal trigger for MC, driving B-cell polyclonal proliferation.
- Antiviral therapy can lead to regression of associated B-cell lymphoproliferative disorders.
- Rituximab offers a safe and effective alternative to immunosuppression for B-cell control.
Conclusions:
- HCV-related MC is an autoimmune manifestation of chronic viral infection.
- Viral eradication and targeted B-cell therapies are key treatment strategies.
- Understanding the interplay between viral infections and B-cell disorders is crucial for patient management.
Related Concept Videos
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Humoral Immune Responses
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Nephrotic Syndrome I : Introduction
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
